RE:RE:RE:RE:New Press Release - Theratechnologies Announces Path to Resume TH1902 Clinical DevelopmentI don't know for sure, of course. But the way I read it was they will need to find a partner to help with both financial and research resources to get it going again. It seems to me the desire to get to positive cash flow is pretty strong since the alternative to getting there quickly is ugly. But the way it is written leaves room for restarting it without a partner, trying to find some good pahse 1 data and then seeking a partner. This would be ideal if they c an find that good data as signing a partner without good data is not only hard but also less lucrative. I just cannot see how they have the money to spend on a restarted trial but I may be being too pessimisitc about that. Let's see how much cash they burned in Q4. I suspect they knew the trial was in trouble midway through Q4 (thus the transition from "we believe we have the key t o the cancer cell" to mostly talkng about anything but cancer on the mid-October conference call. So, they may have been able to slow the cash burn before the end of the quarter. Even then, I doubt it could make a huge difference.
Also, we have to consider the possibility they do another unfortunate share offering or some other dilutive financing to be in a financial position to finish the restarted phase 1. While I say unfortunate, if they ended up getting good results, it likely would be money well spent because even a diluted success in cancer is far superior to a non-diluted exposure to just the two legacy drugs,.
qwerty22 wrote: "Once the Phase 1 clinical trial has resumed"
SPCEO, are you thinking that "resumed" just means getting past the pause with the fda, ie. getting the FDA to allow them to restart? Not necessarily actually, actively recruiting patients again?